Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property Development Limited

Robert W Marquis, Jr

Linda N Casillas

Joshi M Ramanjulu

Daniel F Veber

James Francis Callahan

Pamela A Haile

Joseph J Romano

Adam Kenneth Charnley

Gren Z Wang

Robert Singhaus, Jr

Michael Jonathan Bury

Dennis Shinji Yamashita

Maxwell David Cummings

Yu Ru

Scott Kevin Thompson

Philip Anthony Harris

Michael P DeMartino

Patrick M Eidam

Ami Lakdawala Shah

John F Mehlmann

Xiaoyang Dong

Feng Ren

Xichen Lin

Hui Lei

Xin Zhi Ma

Clark A Sehon

Bryan Wayne King

Robert R Singhaus, Jr

Terry Vincent Hughes

Robert Trout

Michael Reilly

Patric Eidam

Disclosed are compounds having the formula: 

Amino-quinolines as kinase inhibitors

Amino quinazolines as kinase inhibitors

The present invention relates to novel retinoid-related orphan receptor gamma (ROR&#x3b3;) modulators and their use in the treatment of diseases mediated by ROR&#x3b3;.

Compounds

Disclosed are compounds having the formula (Formula I)): wherein R, R, Rand Z are as defined herein, and methods of making and using the same. 

Disclosed are compounds having the formula: wherein X is as defined herein, and methods of making and using the same.

Prodrugs of amino quinazoline kinase inhibitor

Novel calcilytic compounds and methods of using them are provided.

Calcilytic compounds

Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided. 

The present invention provides Calkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.

Protease inhibitors

Novel Calcilytic compounds and methods of using them are provided.

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

Growing community of inventors

Collegeville, PA, United States of America

Robert W Marquis, Jr